Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label follow-up of tofacitinib in juvenile idiopathic arthritis
NL-OMON52164Phase 3Withdrawn
- Sponsor
- Pfizer
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tofacitinib in juvenile idiopathic arthritis (JIA), sponsored by Pfizer. Primary endpoints: Long-term safety and tolerability and Growth and physical development. Planned start Feb 2021; status: withdrawn.
02
Drugs
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NL-OMON52164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52164.